Arthritis Rheumatol:基于RCT数据NSAID使用者严重毒性反应风险评分的推导和验证

2019-03-05 xiangting MedSci原创

风险评分准确地将NSAID使用者的1年严重毒性反应风险进行了分类,该评分有助于识别可安全使用这些药物的患者。

虽然非甾体类抗炎药(NSAIDs)通常用于风湿病,但它们会引起严重的毒性反应。提高风险-收益比需要更准确地了解风险。

研究人员推导并验证了一项随机对照试验中NSAID使用者严重毒性反应的风险评分。已知患血管疾病或有血管危险因素的骨关节炎或类风湿性关节炎患者被分成衍生队列和验证队列。受试者被随机分配至典型剂量的塞来昔布、萘普生或布洛芬组。风险评分预测NSAID使用者严重毒性反应的1年发生率,包括主要的不良心血管事件、急性肾损伤、明显的肠道事件和死亡率。与严重毒性反应显著相关的指标作为纳入最终回归模型的候选项。在发现推导模型在验证集中具有相似的模型拟合后,将队列合并,并计算风险评分。

在推导队列中,显著指标包括年龄、男性、心血管疾病史、高血压糖尿病、吸烟、使用他汀类药物、血清肌酐升高、血细胞比容和关节炎类型。验证队列中的C指数为0.73,总队列为0.71;该模型经过很好的校准。在具有完整数据的总人群中(n=23,735),1,080名患者(4.6%)的预测1年风险<1%,16,273(68.6%)的预测风险为1-4%,6,382名(26.9%)的预测风险>4%。

风险评分准确地将NSAID使用者的1年严重毒性反应风险进行了分类,该评分有助于识别可安全使用这些药物的患者。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2022-10-23 delianjihui

    可以指导临床实践

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2022-10-23 delianjihui

    下载深入学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2022-10-23 delianjihui

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2019-07-30 d830372
  6. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2019-05-16 wjywjy
  7. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2019-03-07 zhaojie88
  8. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2019-03-07 amyloid
  9. [GetPortalCommentsPageByObjectIdResponse(id=2095673, encodeId=617220956e307, content=可以指导临床实践, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:39:17 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095672, encodeId=4f1f20956e2f2, content=下载深入学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:56 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095671, encodeId=412620956e1f7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Sun Oct 23 22:38:27 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972618, encodeId=a63e19e2618ec, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Mar 19 06:26:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793593, encodeId=b14f1e9359363, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jul 30 23:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033871, encodeId=002720338e175, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu May 16 15:26:00 CST 2019, time=2019-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357125, encodeId=d58a135e125c7, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413646, encodeId=a6fd141364635, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Mar 07 02:26:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362030, encodeId=8e783620303f, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Tue Mar 05 12:51:29 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2019-03-05 1e0ece0dm09(暂无匿称)

    谢谢分享谢谢分享

    0

相关资讯

GUT:沃诺拉赞(vonoprazan)vs.兰索拉唑的对照研究!

近期,一项发表在杂志GUT上的研究评估了与兰索拉唑相比,沃诺拉赞(vonoprazan)用于二次预防非甾体抗炎药(NSAID)诱导的消化性溃疡(PU)的非劣性以及其延长使用期间的安全性。此项研究为3期,为期24周的多中心随机双盲(DB)主动对照研究,随后是门诊3期患者,为期≥28周的多中心单盲平行组延伸研究(EXT) (n = 642),均接受长期NSAID治疗且有PU复发风险。患者接受沃诺拉赞(

Aliment Pharmacol Ther:选择性COX-2抑制剂+PPIs可显著降低NSAID相关胃肠道毒性风险

近期一项系统回顾和荟萃分析结果表明,联合选择性COX-2抑制剂和质子泵抑制剂可降低NSAID引起的胃肠道毒性风险。中国香港大学公共卫生和初级保健学院的Jin Ling Tang博士说:“选择性COX-2 NSAID联合PPI的费用很贵,并不对所有使用NSAID的患者推荐该组合。不过该组合是降低NSAID相关溃疡出血风险的最安全和最有效的治疗策略。”为比较当前预防策略降低NSAID引起的胃肠道毒性的

BMJ:NSAID增加急性心梗风险证据确凿

口服非甾体抗炎药(NSAIDs)能增加急性心梗风险的观点被普遍接受。2017年5月,发表在《BMJ》的一项由加拿大、芬兰和德国科学家进行的个体患者数据的贝叶斯Meta分析考察了真实世界中,NSAID使用的急性心肌梗死的风险。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点——目的:旨在描述与口服NSAID使用相关的急性心肌梗死的决定因素、时间过程和风险。设计:系统评价后一级贝叶斯个体患者数据M

JCO:NSAID可显着改善KRAS野生型患者的生存

美国福瑞德哈金森肿瘤研究中心的XinweiHua等报告的一项研究显示,在长期存活的结直肠癌患者中,癌症确诊后常规应用非甾体类抗炎药(NSAID)可显着改善KRAS野生型患者的生存。(J Clin Oncol. 2017年6月15日在线版)常规应用阿司匹林可改善结直肠癌患者的生存期。然而,哪些类型的结直肠癌,以及能从阿司匹林和其他NSAID获益最大的用药时机,这些问题目前尚不清楚。该研究共入组199

Stroke:NSAID与心脑血管疾病风险的关系

有关高危人群用非甾体类抗炎药(NSAID)与其脑血管事件风险关系研究尚有限,因此,台湾学者们评估了短期应用(30天)选择性和非选择性NSAID对高血压患者缺血性和出血性卒中发生风险的影响。结果表明,高血压患者应用NSAID增加其罹患卒中的风险,尤其是缺血性卒中的风险。研究者提示,应对接受NSAID治疗患者进行密切的监测,尤其是高血压患者。相关文章3月3日在线发表于《卒中》(Stroke)杂

J Endod:非甾体抗炎药物作为下牙槽神经阻滞麻醉的术前口服药对治疗不可逆牙髓炎的效果

下牙槽神经阻滞麻醉(IANB)的成功是治疗下颌不可逆牙髓炎的必要条件。这篇系统性的文献回顾的目的是为了评估非甾体抗炎药物(NSAIDs)作为IANB的术前口服药物对治疗不可逆牙髓炎的效果。